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Introduction
The CAG/polyglutamine (CAG/polyQ) disorders are a family of 
9 neurodegenerative diseases caused by similar microsatellite 
expansions in coding regions of unrelated genes (1). Among these 
diseases is spinobulbar muscular atrophy (SBMA), a progressive 
neuromuscular disorder that occurs only in men and is character-
ized by proximal limb and bulbar muscle weakness, atrophy, and 
fasciculations (2). Clinical onset of SBMA occurs in adolescence 
to adulthood and is characterized initially by muscle cramps and 
elevated serum creatine kinase (3, 4). These myopathic features 
commonly precede muscle weakness, which inevitably develops 
as the disease progresses. The causative mutation in SBMA is an 
expansion of a CAG repeat in the first exon of the androgen recep-
tor (AR) gene (5). The expanded glutamine tract promotes hor-
mone-dependent AR unfolding and oligomerization, steps that are 
critical to toxicity. In SBMA, as in other CAG/polyQ disorders, the 
mutant protein disrupts multiple downstream pathways and toxic-
ity likely results from the cumulative effects of altering a diverse 
array of cellular processes including transcription, RNA splicing, 
axonal transport, and mitochondrial function (6–15). Mechanisms 
that lead to the selective impairment of the neuromuscular system 
remain incompletely understood, yet recent studies have estab-
lished that peripheral expression of the polyQ AR in skeletal mus-
cle is an important contributor to this process (16, 17).
In addition to the proteotoxic gain of function, polyQ expansion 
also negatively affects the intrinsic transcriptional activity of the AR 
(6, 8–10). While SBMA patients exhibit signs of partial androgen 
insensitivity, as manifested by diminished fertility and gynecomas-
tia, the extent to which loss of AR function contributes to pathogen-
esis remains poorly understood, mainly because of the difficulty in 
dissociating effects of proteotoxicity from impaired intrinsic tran-
scriptional function. To explore this question, we sought to define 
the consequences of mitigating the transcriptional deficits of the 
polyQ AR by relieving the inhibitory effect of AR posttranslational 
modification by small ubiquitin-like modifier (SUMO) (18, 19).
SUMO proteins share with ubiquitin a common structural 
fold and are reversibly conjugated to lysine residues in target pro-
teins through an enzymatic pathway analogous to ubiquitination, 
but carried out by a distinct set of enzymes (20). AR was one of 
the first proteins shown to be subject to SUMOylation (19), and 
this modification occurs at 2 lysines (K385, K518) in the N-ter-
minal region. These residues are embedded within short amino 
acid motifs that have been functionally defined in AR and other 
sequence-specific factors as exerting a promoter context inhibi-
tory effect (18). As is the case for most proteins, steady-state stoi-
chiometry of SUMOylation of AR is low, likely because of active 
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Hsc70-interacting protein (hCHIP) and HA-tagged ubiquitin. 
Moreover, ubiquitination of both AR variants was enhanced fol-
lowing treatment with YM-1 (Figure 1E), an allosteric regulator 
of Hsp70 that increases polyQ AR degradation (32). These data 
indicate that the KRKR mutation abolishes SUMO modification 
of the polyQ AR without significantly altering ligand-dependent 
localization or ubiquitination.
Preventing SUMOylation enhances transcriptional activity of the 
polyQ AR. To examine the effects of the KRKR mutation on polyQ 
AR transcriptional function, PC12 cells were induced to express 
similar levels of AR10Q, AR112Q, or AR111Q-KRKR (as in Figure 
1A) and then stimulated with R1881 or vehicle control for 24 hours. 
Triplicate RNA samples from each line were collected, and the cor-
responding cDNAs were analyzed by Affymetrix GeneChip micro-
arrays (Figure 2, A–C). A heat map of the 93 genes significantly acti-
vated (in red) or repressed (in blue) by androgen in AR10Q cells and 
the corresponding levels in AR112Q and AR111Q-KRKR is shown 
in Figure 2A. This analysis confirmed a glutamine length–depen-
dent partial loss of AR function with a significant reduction in the 
amplitude of regulation for most genes (Supplemental Table 1; sup-
plemental material available online with this article; doi:10.1172/
JCI73214DS1). Of the 93 ligand-responsive genes identified in 
cells expressing AR10Q, only 32 met criteria for ligand regulation 
(≥1.5-fold change) in AR112Q cells (Figure 2C). Detailed analyses 
revealed that the regulatory deficits in AR112Q cells were broad 
across the set of 93 ligand-responsive genes and affected genes irre-
spective of the relative abundance of their transcripts (not shown). 
Notably, and consistent with the promoter context-dependent 
effects of AR SUMOylation, disruption of the SUMOylation sites 
partially counteracted this polyQ-induced loss of function. AR111Q-
KRKR cells showed enhanced responsiveness to a subset of genes, 
increasing the number of genes meeting the threshold for differ-
ential expression to 49 (Figure 2C). To confirm these data, we ana-
lyzed selected genes by quantitative real-time RT-PCR (qPCR). The 
Ppard gene, drawn from the microarray subset of genes regulated in 
all 3 lines, displayed comparable induction when analyzed by qPCR 
(Figure 2D). In contrast, examination of 2 independent genes from 
the subset regulated only by AR10Q and AR111Q-KRKR (Baiap2, 
Chst1) confirmed a glutamine length–dependent loss of inducibility 
that was reversed and even further enhanced by disruption of the 
SUMOylation sites (Figure 2D). This same pattern of androgen-
responsive changes was observed in PC12 cells expressing AR10Q 
and AR10Q-KRKR (Figure 2E). AR10Q and AR10Q-KRKR dis-
played similar ligand-dependent activation of Ppard, whereas 
AR10Q-KRKR triggered enhanced activation of Baiap2 and Chst1. 
These data are consistent with prior studies using reporter gene 
assays, where disrupting polyQ AR SUMOylation by introduction of 
the KRKR mutations or I384N/V517N substitutions or by deletion 
of the SUMOylation motifs enhanced activation of AR- responsive 
reporter gene constructs (31).
Notably, we also found that the KRKR mutation enhanced the 
total number of genes meeting threshold for ligand responsive-
ness to 246 (Figure 2C). For the 183 genes that met the threshold 
for only AR111Q-KRKR, a comparison with the corresponding 
levels in AR10Q and AR112Q (Figure 2B) revealed that a large 
majority of these genes displayed ligand regulation but did not 
change by 1.5-fold or more (Supplemental Table 2). This outcome 
reversal by SUMO proteases such as SUMO1/sentrin-specific pep-
tidase 1 (SENP1) (21). Nevertheless, transient SUMOylation exerts 
strong inhibitory effects through a distinct surface in SUMO (22) 
that is recognized by SUMO-binding motifs in partner proteins 
(23). Although the exact nature of the SUMO-binding factors 
responsible for the inhibitory effects on AR is not fully defined, 
mechanistic studies indicate that SUMOylation exerts its effects 
preferentially on stably bound receptor-DNA complexes (24) and 
involves a redistribution of AR away from chromatin (25).
SUMOylation has attracted considerable attention for its 
impact on neurodegenerative diseases, including polyQ disorders 
(26, 27). In addition to AR, several mutant proteins that cause neu-
rodegeneration are targets of SUMOylation. The extent to which 
SUMO influences disease pathogenesis varies in a context-depen-
dent manner (28). Here, we take advantage of the modulatory role 
of SUMOylation on AR function to test the hypothesis that dimin-
ished transcriptional activity of the polyQ AR contributes to SBMA 
pathogenesis. In this view, restoring transcriptional function 
would be expected to attenuate some aspects of the disease. Our 
approach is based on the established inhibitory effects of SUMO 
on AR function, the significant loss of transactivation caused by 
polyQ expansion (6–10, 29), and prior studies suggesting that 
native AR function contributes to SBMA pathogenesis (30). To 
test our hypothesis, we used gene targeting to generate a knockin 
mouse line that expresses a polyQ-expanded AR that cannot be 
SUMOylated. Our studies characterizing this new mouse model 
of SBMA, complemented by additional experimental systems in 
vitro, provide a unique avenue for examining the effects of restor-
ing polyQ AR function and serve to dissociate the pathogenic role 
of AR dysfunction from polyQ proteotoxicity in vivo.
Results
Establishment of a cellular model of a SUMOylation-resistant polyQ 
AR. To study the effects of abrogating SUMOylation of the polyQ 
AR, we initially generated PC12 cells expressing tetracycline-
regulated AR10Q, AR112Q, and AR111Q, with its 2 SUMO-accep-
tor lysine residues mutated to arginine (AR111Q-KRKR) (Figure 
1A). With these cells, we tested to determine whether introduc-
ing mutations that prevent SUMOylation affected the response 
of polyQ AR to ligand. In the absence of the synthetic nonaroma-
tizable androgen R1881, all 3 variants of AR displayed a predomi-
nantly cytoplasmic distribution, in agreement with expected 
localization when unbound to ligand (Figure 1, B and C). Upon 
addition of R1881, all 3 AR forms accumulated in the nucleus 
with comparable kinetics (Figure 1B) and both AR112Q and 
AR111Q-KRKR formed ligand-dependent intranuclear aggre-
gates (Figure 1C). To verify that the KRKR mutations interrupt AR 
SUMOylation, we transiently transfected AR112Q and AR111Q-
KRKR cells with HA-tagged SUMO3, then immunoprecipitated 
each polyQ AR variant and probed for HA. Western blot analy-
sis confirmed that polyQ AR remained a target of SUMOylation 
and that the KRKR mutation prevented this modification (Figure 
1D), in line with previous transient expression studies (31). In 
contrast, the KRKR mutation did not alter ubiquitination (Fig-
ure 1E), another lysine-directed posttranslational modification 
of the polyQ AR. Both AR112Q and AR111Q-KRKR were ubiq-
uitinated in cells expressing the human E3 ligase C terminus of 
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found to expand the number of induced and repressed genes (33). 
Taken together, these results demonstrate that, although expan-
sion of the glutamine tract diminishes the responsiveness of genes 
normally regulated by AR, preventing SUMOylation through the 
KRKR mutation partially counteracts these deleterious effects.
is consistent with the predicted enhancement in responsiveness 
to a subset of genes natively regulated by AR as a consequence 
of relief from the inhibitory effects of SUMO. These findings are 
also similar to those recently reported in a prostate cancer cell 
line where the KRKR mutation (in non–polyQ-expanded AR) was 
Figure 1. A cellular model expressing non-SUMOylatable polyQ AR. (A) AR10Q, AR112Q, or AR111Q-KRKR were induced to express AR in the presence of 10 nM 
R1881 for 24 hours, then analyzed by Western blot. Dox, doxycycline. (B and C) AR10Q, AR112Q, and AR111Q-KRKR cells were induced to express AR for 24 hours, 
then treated with R1881 for varying times and immunostained for AR (red). Nuclei were stained by DAPI. (B) Cytoplasmic (score 0) to nuclear (score 4) transloca-
tion was determined at indicated times. Data are mean ± SEM. n = 3 replicate experiments. (C) Arrows indicate nuclei containing aggregates after 24 hours of 
treatment with 10 nM R1881. Scale bar: 2 μm. (D) AR112Q- and AR111Q-KRKR–expressing cells were transfected with HA-SUMO3 and treated with 10 nM R1881 
for 24 hours. Whole-cell lysates (left panel) were immunoprecipitated for AR and blotted for HA or AR (right panel). (E) AR112Q or AR111Q-KRKR cells were trans-
fected with HA-ubiquitin and hCHIP, and treated with YM-1, as indicated. Following incubation with 10 mM MG132, lysates were collected and analyzed for AR 
ubiquitination. Whole-cell lysates (left panel) were immunoprecipitated for AR and blotted for AR and HA (middle and right panels).
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disrupting AR SUMOylation on ligand-dependent gene regulation 
in vivo. To accomplish this, a cohort of WT, AR113Q, and AR113Q-
KRKR adult males were surgically castrated in order to suppress 
endogenous ligand activation of AR. Three weeks after orchiecto-
my, animals were treated with testosterone propionate or vehicle by 
i.p. injection and tissues were harvested after 16 hours. The expres-
sion of well-characterized androgen-induced genes in prostate was 
examined by qPCR (Figure 4A). Our analysis showed that the strong 
ligand-induced expression of Nkx3-1 in WT males was absent in the 
AR113Q line, but was fully restored in AR113Q-KRKR mice. A simi-
lar pattern was also observed for Fkbp5. In the case of Pbsn, the mod-
est and not significant induction in WT males was absent in ARQ113 
mice, but was strongly enhanced in AR113Q-KRKR mice. To deter-
mine effects on androgen-regulated gene expression in skeletal 
muscle, we harvested the levator ani-bulbocavernosus (LABC), a 
muscle that expresses high levels of AR. We used an AR-signaling 
target array to identify candidate androgen-responsive genes in 
muscle from WT mice (data not shown). We selected 7 genes that 
were repressed by ligand treatment and confirmed that all tran-
scripts were significantly decreased in muscle following androgen 
treatment of WT males (Figure 4B). In AR113Q males, none of these 
genes responded to androgen treatment, whereas appropriate regu-
Generation of AR113Q-KRKR knockin mice. To investigate the 
influence of SUMOylation in vivo, we used gene targeting in order 
to generate knockin mice that express the polyQ AR, with K385 and 
K518 both mutated to arginines. We modified the targeting vector 
used previously to generate our existing AR113Q line of knockin 
mice by introducing the KRKR mutations (Figure 3A). We verified 
correct recombination of the targeted exon 1 into the mouse AR 
gene by Southern blot analysis in JM8.F6 cells, an embryonic stem 
(ES) cell line from the C57BL/6N strain (Figure 3B). After germline 
transmission of the targeted allele from chimeric founders to F1 het-
erozygous females, we crossed these females to C57BL/6J WT males 
and assessed subsequent inheritance of the AR113Q-KRKR allele by 
PCR (Figure 3C). For the purposes of phenotypic characterization in 
this study, we used AR113Q male mice backcrossed for more than 
10 generations to the C57BL/6J background, N1 AR113Q-KRKR 
male mice, and WT littermate males from both lines. Females from 
both AR113Q lines were similarly fertile, and both AR113Q alleles 
were inherited in the expected Mendelian ratios (data not shown). 
Male mice from the AR113Q and AR113Q-KRKR lines were indistin-
guishable prior to disease onset at sexual maturity.
Preventing AR SUMOylation alters ligand-dependent gene regula-
tion in vivo. We initially sought to determine the consequences of 
Figure 2. Disruption of polyQ AR SUMOylation potentiates AR function. (A) Heat map showing expression of genes activated (red) or repressed (blue) 
1.5-fold or more by AR10Q cells compared with expression in AR112Q and AR111Q-KRKR cells. (B) Heat map showing expression of 183 androgen-responsive 
genes in AR111Q-KRKR cells that change less than 1.5-fold in AR10Q and AR112Q cells. (C) Venn diagram illustrating the number and overlap of androgen-
responsive genes in AR10Q (black circle), AR112Q (blue circle), and AR111Q-KRKR cells (red circle). (D) Expression of candidate genes (Ppard, Baiap2, and 
Chst1 in black, red, and purple, respectively) identified in A was analyzed by qPCR. Data shown are mean ± SEM (n = 3). ****P < 0.0001 by ANOVA. (E) 
Expression of candidate genes (Ppard, Baiap2, and Chst1 in black, red, and purple, respectively) in AR10Q and AR10Q-KRKR cells was analyzed by qPCR. 
Data shown are mean ± SEM (n = 3). **P < 0.01; ***P < 0.001; ****P < 0.0001 by ANOVA.
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characterization of muscle function beyond assessment of grip 
strength, we examined exercise capacity by treadmill running 
until exhaustion. By this measure we detected a significant dec-
rement in exercise endurance in AR113Q mice (Figure 6C), con-
sistent with other measures of functional decline in SBMA muscle 
(35, 36). Strikingly, KRKR mutations in the polyQ AR yielded a 
profound rescue of exercise capacity to levels equivalent to those 
of WT mice. This functional rescue persisted in mice aged up to 9 
months (Figure 6D). Since many trophic effects of androgens on 
muscle are thought to be a consequence of ligand-activated gene 
regulation, we hypothesized that the recovery in KRKR mutants 
reflected a restored trophic support that would be dependent 
upon ligand. To test this possibility, we applied the same exercise 
paradigm to AR113Q-KRKR males that had been castrated at 5 
to 6 weeks and to WT females. Exercise trials of these 2 cohorts 
revealed substantially less exercise capacity compared with 
gonadally intact males regardless of glutamine tract length (Fig-
ure 6C). These results confirmed the supportive role of androgens 
in the development of exercise endurance and in directing the res-
cue in SUMO-resistant SBMA mice.
Since early death is another phenotypic feature of AR113Q 
mice, we followed cohorts of WT, AR113Q, and AR113Q-KRKR 
mice and monitored survival rates. In line with previous charac-
terization (36), AR113Q mice demonstrated a precipitous decline 
in survival beginning at 13 weeks (Figure 6E). None of these mice 
survived past 40 weeks (n = 10). In contrast, AR113Q-KRKR mice 
exhibited a profound extension of life span. Through 40 weeks, 
only 1 death occurred in the experimental cohort (n = 10). This 
rescue of early death was significant (P < 0.0001) and took place 
despite a lack of discernible differences in disease onset between 
the SUMOylation-competent and SUMOylation-deficient AR113Q 
lines. We defined disease onset as the age at which grip strength 
of mutant males was 10% less than the mean of age-matched WT 
controls and found no difference between AR113Q and AR113Q-
KRKR males (Figure 6E). Accordingly, the equivalent disease 
onset coupled with life span extension resulted in a significant 
lation was observed in AR113Q-KRKR males. Taken together, these 
data are consistent with our PC12 cellular model and demonstrate 
that disrupting polyQ AR SUMOylation restores acute androgen 
responsiveness to AR target genes in vivo.
AR113Q-KRKR males demonstrate partial androgen compro-
mise. Since partial loss of AR function and features of androgen 
insensitivity are molecular and phenotypic hallmarks of SBMA, 
we examined several measures of androgen function on the hypo-
thalamic-pituitary-gonadal (HPG) axis in AR113Q-KRKR mice at 
13 to 15 weeks of age. Compared with WT mice, both AR113Q and 
AR113Q-KRKR mice demonstrated testicular and seminal vesicle 
atrophy and reduced sperm counts (Figure 5A). Modest eleva-
tions in serum testosterone and luteinizing hormone (LH) were 
evident in both AR113Q and AR113Q-KRKR males, but because of 
variability between animals, these changes did not reach statisti-
cal significance (Figure 5B). We also analyzed testicular expres-
sion of the gene encoding 3-β-hydroxysteroid dehydrogenase 
type I (3βHSD-I, Hsd3b1), an enzyme responsible for ketosteroid 
hormone synthesis in Leydig cells in response to LH and whose 
expression is indicative of androgen insensitivity (34). Consistent 
with the endocrine tissue pathology and serum studies, we found 
similar increases in Hsd3b1 mRNA in testes from both 113Q lines 
of mice (Figure 5C). These data demonstrate that compromise of 
the androgen axis remains evident when polyQ AR SUMOylation 
is prevented. Furthermore, we speculated that chronically 
enhanced AR activity in the KRKR mutant could lead to inhibition 
of the HPG axis in aged males. Consistent with this notion, adult 
AR113Q-KRKR males at 7 to 9 months exhibited more severe tes-
ticular atrophy and decreased sperm counts compared with simi-
larly aged AR113Q males (Figure 5D).
Behavioral and neuromuscular phenotypes in AR113Q-KRKR 
mice. As the phenotype of AR113Q mice includes decreased body 
mass and grip strength, we also evaluated these parameters in 
AR113Q-KRKR mice and found indistinguishable deficits (Figure 
6, A and B). The reduction in these measures became evident at 
approximately 12 weeks and persisted thereafter. To broaden our 
Figure 3. Generation of AR113Q-KRKR knockin 
mice. (A) Schematic representation depicting 
AR113Q-KRKR targeting vector. Sphl restriction 
sites, 5′ and 3′ probes for Southern blot analysis, 
glutamine tract, lysine-to-arginine mutations, and 
floxed neomycin resistance cassette are indicated. 
Diagram modified from ref. 55. (B) Southern blot 
analysis of ES cell DNA after Sphl digestion with 
the 5′ and 3′ probes indicated in A before (lanes 
1 and 4) and after (lanes 2 and 5) homologous 
recombination. Lanes 3 and 6 contain control liver 
DNA from previously targeted AR113Q knockin line. 
L, ladder. (C) PCR primers were used to amplify 
sequences from a WT female (lane 1), F1 AR113Q-
KRKR female (lane 2), and N1 AR113Q-KRKR male 
(lane 3) produced by the female in lane 2.
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extension of disease duration (P < 0.02) in the SUMOylation-defi-
cient SBMA mice (Figure 6E). Taken together, these results show 
that abrogating polyQ AR SUMOylation, which enhances AR tran-
scriptional function, exerts profound and long-lasting beneficial 
effects on exercise endurance and survival.
Rescue of type I fiber atrophy and gene-expression changes in 
AR113Q-KRKR muscle. To explore the mechanism underlying 
phenotypic rescue in AR113Q-KRKR mice, we initially sought to 
determine whether mutant forms of the AR were equivalently 
expressed. Immunoprecipitation (IP) of AR from quadriceps 
muscle and spinal cord demonstrated that levels of AR113Q and 
AR113Q-KRKR were similar (Figure 7A and Supplemental Figure 
1). Comparable levels of AR protein were also detected in testis 
of WT, AR113Q, and AR113Q-KRKR mice (Figure 7B and Supple-
mental Figure 1). Since AR113Q mice display frequent accumu-
lation of intranuclear aggregates of polyQ AR in skeletal muscle 
(36), we analyzed sections of LABC and quadriceps muscle from 
mice aged 13 to 15 weeks. While quadriceps nuclei in WT muscle 
rarely showed punctate AR intranuclear staining (5.5% ± 2.3%), 
nuclei from both AR113Q and AR113Q-KRKR quadriceps muscle 
showed substantially higher and similar amounts of polyQ AR 
aggregates (26.9% ± 2.2% and 29.4% ± 1.9%, respectively) (Figure 
7C). A similar pattern was observed in the LABC. These analyses 
indicate that phenotypic rescue was not attributable to diminished 
expression or aggregation of AR113Q-KRKR.
Rescue of exercise endurance and survival was also not asso-
ciated with attenuation of muscle atrophy or skeletal muscle 
gene-expression changes indicative of denervation. The tibialis 
Figure 4. Expression of androgen-responsive genes in prostate and skeletal muscle. WT (black bars), AR113Q (white bars), and AR113Q-KRKR (gray bars) 
adult males underwent orchiectomy and then 3 weeks later were treated with 200 mg testosterone propionate i.p. (+) or vehicle (–). Prostate (A) and LABC 
muscle (B) were harvested after 16 hours. Expression of AR-responsive genes was analyzed by qPCR. Data shown are mean ± SEM (n = 3/group). *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001; NS, not significant by ANOVA.
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anterior (TA) muscle showed significant atrophy in both AR113Q 
and AR113Q-KRKR mice compared with WT (Figure 8A). Both 
AR113Q lines expressed equivalent levels of AR mRNA and 
showed increased expression of acetylcholine receptor-α subunit 
and myogenin mRNAs in quadriceps muscle. A similar trend was 
observed for the expression of Myod mRNA (Figure 8B). Unex-
pectedly, these measurements of muscle pathology were slightly 
accentuated in AR113Q-KRKR mice despite rescue of exercise 
capacity and survival. This suggested that alterations in other 
muscle properties mediated the beneficial response to ligand acti-
vation of AR113Q-KRKR.
An important determinant of exercise performance and meta-
bolic profile is the fiber type composition of skeletal muscle. Type I 
(slow twitch) fibers are rich in mitochondria, fatigue resistant, and 
reliant on oxidative metabolism, while type II (fast twitch) fibers 
are mitochondria poor, fatigue susceptible, and dependent on gly-
colytic metabolism (37, 38). Given the notable androgen-depen-
dent improvement in exercise endurance in AR113Q-KRKR males, 
we performed immunostaining for fiber type–specific heavy-chain 
myosins on soleus muscle because of its mixed fiber type composi-
tion. In contrast, both the TA and quadriceps muscles are type II 
fiber predominant (39, 40). In AR113Q soleus muscle, we observed 
atrophy across all fiber types (Figure 8, C and D). In contrast, soleus 
from AR113-KRKR mice contained type I fibers that were remark-
ably spared from atrophy (Figure 8, C and D). Quantification of 
cross-sectional area demonstrated a significant rescue in the distri-
bution and mean type I fiber size (Figure 8D). This rescue of muscle 
atrophy was not seen in type II fibers of AR113Q-KRKR muscle, nor 
was it observed in type I fibers of AR113Q-KRKR mice following 
castration (Figure 8D). These data reveal that the improved exer-
cise endurance in AR113Q-KRKR was associated with rescue of 
type I fiber atrophy and suggest that this fiber-selective effect is 
mediated by trophic support from the KRKR receptor.
To explore whether AR113Q-KRKR also affects muscle pre-
dominantly composed of type II fibers despite the absence of mor-
phological rescue of atrophy, we used RNA-Seq to analyze gene 
expression in quadriceps muscle from WT, AR113Q, and AR113Q-
KRKR males at 14 weeks. Pairwise comparisons enabled the iden-
tification of differentially expressed genes in WT versus AR113Q 
muscle and WT versus AR113Q-KRKR muscle. We queried these 
lists against a publicly available database of literature-derived 
androgen-responsive genes that includes 993 mouse genes (41). 
This strategy identified 107 differentially expressed androgen-
response genes in quadriceps muscle of WT versus AR113Q males 
(Figure 9A and Supplemental Table 3). Ninety-six of these genes 
were also differentially expressed in WT versus AR113Q-KRKR 
muscle. As shown in the heat map (Figure 9B), similar expression 
changes were identified for the majority of these genes in AR113Q 
and AR113Q-KRKR muscle, though AR113Q-KRKR muscle gen-
erally showed a greater magnitude of change. Interestingly, this 
analysis also identified an additional 221 genes that were differen-
tially expressed in AR113Q-KRKR, but not AR113Q muscle (Figure 
9, A and B), suggesting that the mutation had expanded the set of 
AR-regulated genes in skeletal muscle much as it had done in vitro 
(Figure 2). Pathway analysis using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) revealed that 
these 221 genes were highly enriched for mitochondria-related 
functional categories (Table 1), indicating that altered expression 
of genes regulating energy metabolism correlated with enhanced 
exercise endurance. Taken together, these data suggest that dis-
Figure 5. Characterization of the HPG axis in AR113Q-KRKR mice. (A) Testes and seminal vesicles were collected at 13 to 15 weeks and analyzed by weight 
(left and middle panels). Epididymes were collected and sperm count determined (right panel). Data are shown as mean ± SEM (n = 6 per group). *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001 by ANOVA. (B) Serum samples (n = 6 per group) were collected at 13 to 15 weeks and analyzed for levels of testos-
terone (T) and LH. Data are shown as mean ± SEM. (C) Total RNA was extracted from testes from WT, AR113Q, and AR113Q-KRKR mice (n = 3 per group) at 
13 to 15 weeks and analyzed for Hsd3b1 expression by qPCR. Data are shown as mean ± SEM. ****P < 0.0001 by ANOVA. (D) Testis weight and epididymal 
sperm count from males at 7 to 9 months. Data are shown as mean ± SEM. *P < 0.05; ***P < 0.001; ****P < 0.0001 by ANOVA.
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type II muscle fibers as well, despite the lack of rescue of fiber 
atrophy. This conclusion is supported by the identification of 
numerous gene-expression differences in quadriceps muscle of 
AR113Q-KRKR versus WT males that are not similarly detected 
in AR113Q muscle, many of which cluster in mitochondria-relat-
ed pathways. Included in the list of genes selectively upregulated 
in AR113Q-KRKR muscle are those encoding the mitochondrial 
proteins translocase of mitochondrial membrane 20 homolog 
(TOMM20), NADH dehydrogenase (ubiquinone) Fe-S protein 
3 (NDUFS3), hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase, β subunit (HADHB), cytochrome 
c, and cytochrome oxidase subunit VIIc. The beneficial effects of 
the KRKR mutation within skeletal muscle are consistent with 
recent studies demonstrating a critical role of peripheral polyQ 
AR expression in SBMA pathogenesis (16). The KRKR mutation 
within the polyQ AR also leads to an almost complete rescue of 
early death and a marked extension of disease duration. As the 
phenotypic rescue of AR113Q-KRKR males occurs without evi-
dence of diminished polyQ AR expression or aggregation and is 
hormone dependent, we conclude that the beneficial effects of 
abrogating SUMOylation are mediated by enhanced transcrip-
tional function of the mutant receptor. Notably, the conclusion 
that ligand activation of the receptor’s transcriptional function 
is beneficial to SBMA mice is distinct from that drawn from an 
analysis of a Drosophila model of SBMA in which native function 
of the AR was implicated as indispensable for disease pathogen-
esis (30). In contrast, our analyses demonstrate that disrupting 
polyQ AR SUMOylation enhances its transcriptional function 
and rescues key aspects of SBMA pathology. These results argue 
ruption of AR113Q SUMOylation promotes hormone-dependent 
trophic effects on skeletal muscle mediated by enhanced activity 
of the receptor as a transcriptional regulator.
Discussion
In this study of SBMA pathogenesis, we sought to disentangle 
polyQ length–dependent proteotoxicity from the partial loss of AR 
function to discern the relative contribution of each mechanism to 
the disease. To accomplish this goal, we selectively counteracted 
functional alterations in the polyQ AR by relieving the transcrip-
tional inhibitory effect of SUMOylation. We show that mutation 
of the SUMO-acceptor sites in AR exon 1 specifically prevents 
SUMOylation of polyQ AR without altering ligand-induced nucle-
ar translocation, formation of intranuclear inclusions, or steady-
state protein levels. Consistent with the established repressive role 
of SUMO on AR function, the SUMOylation-deficient polyQ AR 
displays broadly enhanced transcriptional activity in both cell cul-
ture and mice, with a profile that partially counteracts the polyQ-
mediated loss of function. Male mice generated by gene targeting 
to express AR113Q-KRKR develop normally and express a pheno-
type only after reaching sexual maturity.
Intriguingly, AR113Q-KRKR male mice exhibit a substantial 
recovery of exercise capacity compared with AR113Q males. This 
rescue persists as animals age despite decrements in exercise 
fitness across all genotypes. Moreover, this rescue is hormone 
dependent and is associated with recovery of type I muscle fiber 
size, demonstrating that ligand-dependent activation of AR113Q-
KRKR provides marked trophic support to muscle. It is likely that 
ligand activation of AR113Q-KRKR exerts beneficial effects on 
Figure 6. Phenotypic characterization of 
AR113Q-KRKR knockin mice. (A) WT, AR113Q, 
and AR113Q-KRKR male mice (n = 10 per group) 
were weighed and (B) assessed for forelimb 
grip strength every 2 weeks. Data shown are 
mean ± SEM. (C) WT (n = 7), AR113Q (n = 6), 
AR113Q-KRKR male mice (n = 6), castrated 
AR113Q-KRKR males (AR113Q-KRKR-C, n = 4), 
and WT females (n = 4) were exercised until 
exhaustion at 13 to 15 weeks of age, and total 
time and distance run were recorded. Data are 
mean ± SEM. *P < 0.05; **P < 0.01 by ANOVA. 
(D) WT, 113Q, and 113Q-KRKR (n = 3 per group) 
males were exercised until exhaustion at 7 to 9 
months of age, and total time and distance run 
were recorded. Data are mean ± SEM. *P < 0.05 
by ANOVA. (E) WT, AR113Q, and AR113Q-KRKR 
male mice (n = 10 per group) were followed for 
overall survival (left panel, P < 0.0001 113Q vs. 
113Q-KRKR by Mantel-Cox log-rank test), and 
both 113Q knockin mouse lines were monitored 
for disease onset (middle panel, P = 0.6) and 
disease duration (right panel, P < 0.02).
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organs, could be considered. Whether such SARMS can provide 
beneficial effects to muscle in a manner that outweighs ligand-
dependent proteotoxicity awaits future testing.
Unexpectedly, endocrine pathology, including seminal vesicle 
and testicular atrophy, sperm count, and Hsd3b1 mRNA expression 
are unaffected by AR SUMOylation. These findings raise the possi-
bility that proteotoxicity of the polyQ AR, and not simply partial loss 
of transactivation function, contributes to deficits in the HPG axis, a 
conclusion that is in accordance with our earlier analysis of AR113Q 
mice (45). Alternatively, the HPG axis may be particularly sensitive to 
altered regulation of AR target genes by the SUMOylation-deficient 
AR, perhaps due to tissue-specific differences in AR SUMOylation. 
This latter view is consistent with the androgen-insensitivity pheno-
type of patients with perturbed AR SUMOylation due to germline 
mutations in the first SUMOylation motif of AR (46).
Prior studies have suggested a modulatory role for SUMO 
in models of SBMA. Disrupting overall SUMOylation worsens 
the SBMA phenotype in a Drosophila model (47), and enhancing 
SUMOylation reduces polyQ AR aggregates, which are thought 
to reflect protein unfolding and the process that underlies pro-
teotoxicity (31). We suspect that our results are not inconsistent 
with these findings. The Drosophila study used an amino-terminal 
fragment of the AR that lacks the SUMOylation sites and ligand-
binding domain to define effects from global impairment of the 
SUMO pathway. This contrasts with the specific modulation of 
AR SUMOylation reported here. Similarly, the inhibitory effects of 
AR SUMOylation on aggregation require a high stoichiometry of 
against a purely propathogenic role of native AR function in dis-
ease. As Drosophila lack endogenous androgen-responsive genes, 
this model is likely insensitive to trophic actions mediated by the 
ligand-activated receptor.
Not all aspects of the phenotype of AR113Q males are res-
cued in AR113Q-KRKR mutants. Disruption of SUMOylation 
fails to significantly modify certain aspects of muscle pathology, 
including weight of muscles that are primarily composed of type 
II fibers, grip strength, and gene-expression changes indicative 
of denervation. Although type I fibers are only a small fraction 
of overall skeletal muscle mass in mice, they are much more 
abundant in humans (42), suggesting that strategies to target 
AR SUMOylation may have greater beneficial effects in SBMA 
patients. It is also likely that trophic effects of the ligand-acti-
vated AR113Q-KRKR are beneficial to additional cell types and 
that these actions could contribute to overall health of SBMA 
mice. This suggests that activating androgen-regulated tro-
phic pathways that are stimulated by the KRKR receptor may 
be beneficial to SBMA patients. A potential approach would be 
to suppress SUMO modification of AR by inhibiting the activity 
of E3 ligases, such as members of the protein inhibitor of acti-
vated STAT (PIAS) family (43), or by stimulating the activity of 
SENP1, the main SUMO peptidase responsible for deconjugating 
SUMO from AR (44). We are actively pursuing the discovery of 
agents that can regulate the activity of these enzymes. Alterna-
tively, selective AR modulators (SARMS) that exert strong ana-
bolic effects in skeletal muscle, but show limited activity in other 
Figure 7. Expression and aggregation of AR113Q and AR113Q-KRKR are 
similar. (A) AR expression in quadriceps and spinal cord from WT, AR113Q, 
and AR113Q-KRKR mice was analyzed by IP and Western blot. GAPDH 
shows similar input protein levels. (B) AR expression in testis. Hsp90 
controls for loading. (C) Immunofluorescence staining for AR (red) in quad-
riceps and LABC. Nuclei were stained by DAPI (blue). Scale bar: 25 μm. At 
right, percentage of nuclei with AR-reactive puncta in the quadriceps. Data 
are mean ± SEM. n = 3 mice per genotype. ****P < 0.0001 by ANOVA.
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Methods
Antibodies. Primary antibodies used for Western blot analysis were 
against AR (N-20, Santa Cruz Biotechnology Inc.), Hsp90 (H-114, San-
ta Cruz Biotechnology Inc.), and HA (HA-11, Covance). Primary anti-
bodies for immunofluorescence were against AR (N-20, Santa Cruz 
Biotechnology Inc.), type I/slow-twitch heavy-chain myosin (A4.840, 
DSHB, University of Iowa, Iowa City, Iowa, USA), and type II/ 
fast-twitch heavy-chain myosin (Ab-2, Thermo Scientific). Horserad-
ish peroxidase–conjugated secondary antibodies used for Western 
blot analysis were from Bio-Rad. Alexa Fluor 555, Alexa Fluor 488, 
and wheat germ agglutinin Alexa Fluor 488 conjugate antibodies 
used for immunofluorescence were from Invitrogen. FITC-conju-
gated donkey anti-mouse IgM was from Jackson ImmunoResearch. 
For IP experiments, the anti-AR antibody PG-21 (Millipore) was used, 
and pulldown was performed with protein A–agarose beads (Santa 
Cruz Biotechnology Inc.).
Cell culture, Western blot, and IP. PC12 cells expressing tetracycline-
regulated AR10Q and AR112Q have been described previously (54). 
Tet-ON AR111Q-KRKR cells were generated by stable transfection of 
pTRE-AR(111-CAG)-KRKR, as described earlier (55). The construct 
was generated by excising a portion of p5HB-hAR24Q-KRKR con-
taining the K385R and K518R mutations with NruI/Tth111I and clon-
ing the fragment into pTRE-AR(111-CAG). The codons for K385 and 
K518 were AAG and AAA, respectively, and were mutated to codons 
for arginine AGA and CGA, respectively. Both K-to-R mutations and 
modification. Thus, in cell culture, introducing the KRKR muta-
tions into the AR without inducing high levels of SUMOylation 
does not modulate polyQ AR aggregation (31), a finding similar to 
our observations in vivo (Figure 7C).
Select point mutations in polyQ proteins exert varying influ-
ence on pathogenesis by modifying protein localization, func-
tion, or stability. In spinocerebellar ataxia type 1 (SCA1), disease 
is ameliorated by diminishing association of polyQ ataxin-1 with 
the transrepressor Capicua through the S776A mutation or by pre-
venting nuclear transport through nuclear localization sequence 
disruption (48, 49). Consistent with these studies, phosphomi-
metic S776D ataxin-1 recapitulates toxicity, and pathogenic S776 
phosphorylation and subsequent nuclear transport are prevented 
by association with 14-3-3 (50, 51). In SCA7, point mutations in 
the NES signal of polyQ ataxin-7 reduce nuclear export and exac-
erbate toxicity (52). Phosphomimetic mutations at Ser13 and 
Ser16 in polyQ huntingtin rescue disease and aggregation, while 
phospho-null mutations iterate pathogenesis (53). In this regard, 
we demonstrate ameliorative effects of KRKR point mutations 
in the polyQ AR that modulate AR function without modifying 
intracellular localization or aggregation. This new disease model 
advances our understanding of SBMA pathogenesis by demon-
strating beneficial effects of enhancing function of the polyQ AR 
and revealing key features of AR SUMO modification that may be 
exploited for therapeutic targeting.
Figure 8. Rescue of type I fiber atrophy in AR113Q-KRKR males. (A) TA muscles were harvested from both hind limbs and weighed (n = 6 per group). 
Data are mean ± SEM. **P < 0.01; ****P < 0.0001 by ANOVA. (B) AR (Ar), nicotinic acetylcholine receptor-a subunit (Chrna1), myogenin (Myog), and MyoD 
(Myod) mRNA were analyzed in quadriceps by qPCR (n = 6 per group). *P < 0.05; ***P < 0.001; ****P < 0.0001 by ANOVA. (C) Representative type I  
slow-twitch heavy-chain myosin (green) and type II fast-twitch heavy-chain myosin (red) staining in soleus. Basement membrane stained with wheat 
germ agglutinin (green). Scale bar: 50 μm. (D) Mean area ± SEM and fiber size distribution of type I and type II fibers (n = 3 mice per group, ≥75 fibers per 
mouse). **P < 0.01; ****P < 0.0001 by ANOVA.
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were determined by modified protein assay (Bio-Rad). After boiling 
at 100°C for 5 minutes in loading buffer, all protein samples were 
resolved on 7% or 10% SDS-PAGE gels, transferred to nitrocellulose 
membranes on a semi-dry transfer apparatus (Bio-Rad), and probed 
by the indicated antibodies. Detection was performed by chemilu-
minescence. For IP, 1500 μg of protein lysate from mouse tissues in 
500 μl of RIPA buffer was incubated with 10 μg of PG-21 antibody 
overnight at 4°C. Protein A–agarose beads were prewashed 3 times in 
RIPA, then incubated in IP samples for 1 hour at 4°C. Bead-antibody 
complexes were then centrifuged in filtered spin columns (Thermo 
Scientific), washed 4 times in lysis buffer, and eluted by boiling in 
loading buffer for 5 minutes at 100°C. Testis lysates were obtained 
by homogenization and centrifugation at 13,000 g for 10 minutes at 
4°C. Protein concentrations were determined as described above, and 
lysates were resolved on a 7.5% SDS-PAGE gel.
AR ubiquitination and SUMOylation studies. For analysis of ubiqui-
tination, PC12 cells expressing AR112Q or AR111Q-KRKR were plated 
at 4 × 106 cells in a poly-d-lysine–coated 60-mm dish (BD Falcon) and 
transiently transfected with plasmids encoding hCHIP (1.5 μg) and 
HA-His-ubiquitin (4.5 μg) using Lipofectamine 2000 (Life Technolo-
gies). Cells were treated with 1 μg/ml doxycycline and 10 nM R1881 
and then with 1 μM YM-1 (last 24 hours) and 10 μM MG132 (last 16 
hours). 48 hours after transfection, cell pellets were resuspended in 
IP lysis/wash buffer (0.025 M Tris, 0.15 M NaCl, 0.001 M EDTA, 1% 
NP-40, 5% glycerol; pH 7.4) containing 1 tablet/10 ml of complete 
Mini-Protease Inhibitor Mix (Roche) and 5 mM N-ethylmaleimide. 
Samples were sonicated and centrifuged at 13,000 g for 10 minutes at 
4°C. 400 μg of protein lysate was incubated on a rotator overnight at 
4°C with 2 μg of anti-AR antibody (Santa Cruz Biotechnology Inc.) or 
nonimmune rabbit IgG. 20 μl of prewashed protein A–agarose beads 
(Santa Cruz Biotechnology Inc.) was added, and samples were incu-
bated for 1 additional hour at 4°C. Protein-antibody-bead complexes 
were washed 6 times in IP lysis/wash buffer in filtered spin columns 
(Thermo Scientific), and proteins were eluted by boiling in SDS-load-
ing buffer for 5 minutes at 100°C. A similar protocol was followed for 
analysis on SUMOylation, except that cells were transfected with plas-
mid encoding HA-SUMO3. Lysates were collected 24 hours after the 
addition of 1 μg/ml doxycycline and 10 nM R1881 in IP lysis/wash buf-
fer containing 20 mM N-ethylmaleimide.
Generation of knockin mice. Knockin mice with AR allele contain-
ing 113 CAG repeats were derived using gene targeting as described 
previously (56). To generate AR113Q-KRKR mice, this strategy was 
modified by using the previously described AR113Q-targeting vector 
as a template. Briefly, a portion of p5HB-hAR24Q-KRKR containing 
the K385R and K518R mutations was excised as an NruI/XhoI frag-
ment and cloned into pLP1-AR113Q. The codons for K385 and K518 
were AAG and AAA, respectively, and were mutated to codons for 
arginine AGA and CGA, respectively. Both K-to-R mutations and the 
the CAG repeat tract-length were verified by sequencing. Induc-
tion of AR expression in AR10Q, AR112Q, and AR111Q-KRKR cells 
to equivalent protein levels was performed with 50 ng/ml, 3 ng/ml, 
and 500 ng/ml doxycycline (Clontech), respectively, in the pres-
ence of 10 nM R1881 or ethanol vehicle for 24 hours unless otherwise 
indicated. Cells were grown and passaged on poly-d-lysine–coated 
flasks in high-glucose phenol-red–free DMEM (Invitrogen) contain-
ing 10% charcoal-stripped horse serum (Invitrogen), 5% charcoal-
stripped FBS (Atlantic Biologicals), 100 units/ml penicillin/strep-
tomycin (Invitrogen), 200 μg/ml hygromycin B (Invitrogen), and 
100 μg/ml G418 (Invitrogen) at 37°C in 10% CO2. For Western blot 
analysis, cells were washed twice and collected by cell scraper in 
PBS, then lysed in RIPA buffer supplemented with Halt phosphatase 
inhibitors (Thermo Scientific), complete protease inhibitors (Roche), 
and 20 mM N-ethylmaleimide (Sigma-Aldrich) to irreversibly inhibit 
SUMO proteases. Whole-cell lysates were preclarified by centrifu-
gation at 15,000 g for 15 minutes at 4°C. Protein concentrations 
Figure 9. Gene-expression differences in quadriceps muscle of WT, 
AR113Q, and AR113-KRKR males. Muscle was harvested from 14-week-old 
males (n = 3/genotype), and gene expression was analyzed by RNA-Seq. 
(A) Venn diagram illustrating the number and overlap of differentially 
expressed (≥ 1.5-fold) androgen-responsive genes in WT versus AR113Q 
(green circle) and WT versus AR113Q-KRKR (red circle). (B) Heat map of 
differentially expressed androgen-responsive genes in WT versus AR113Q 
or AR113Q-KRKR muscle.
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flash frozen in liquid nitrogen for biochemical analysis 
or mounted on OCT blocks for cryosectioning. Epidid-
ymes were also collected at this time, minced in 4 ml of 
PBS, incubated for 10 minutes at room temperature with 
gentle agitation, centrifuged for 1 minute at 500 g, and 
applied to a hemacytometer to determine sperm counts. 
For tissue analyses, quadriceps muscle and lumbar spinal 
cord were minced, lysed by agitation at 4°C for 1 hour, 
and homogenized in RIPA buffer containing phosphatase 
and protease inhibitors. Tissue lysates were then clarified 
at 13,000 g for 10 minutes at 4°C. Protein concentrations 
were determined by modified protein assay (Bio-Rad).
Measurement of serum hormone levels. Serum was col-
lected from mice at 13 to 15 weeks by cardiac puncture, 
and testosterone and LH levels were determined by 
radioimmunoassay (RIA) and sandwich assay, respec-
tively, by the University of Virginia Center for Research 
in Reproduction Ligand Assay and Analysis Core Facility 
(Charlottesville, Virginia, USA). The sensitivities of the testosterone 
RIA and LH assay were 10 ng/dl and 0.07 ng/dl, respectively.
Exercise studies. To analyze exercise capacity, a protocol for tread-
mill running was used as previously described (58). First, mice under-
went 2 days of training on an Exer3/6 treadmill (Columbus Instru-
ments), with day 1 consisting of 5 minutes of running at 8 m/min and 
day 2 consisting of 5 minutes of running at 8 m/min followed by 5 min-
utes at 10 m/min. On day 3, mice ran using a graded protocol consist-
ing of 10 m/min for 40 minutes, then increasing speed by increments 
of 1 m/min every 10 minutes for a total of 30 minutes, and followed by 
increasing speed by increments of 1 m/min every 5 minutes until mice 
were exhausted. Exhaustion was defined as mice making no attempt to 
exercise for 5 seconds. Assessment of endurance in castrated AR113Q-
KRKR males was performed after orchiectomy at 6 weeks of age as 
previously described (36). Briefly, following anesthetization with iso-
flurane, the pelvic area was shaved and opened bilaterally with 1-cm 
incisions to reveal testes for removal, then closed with suture material.
Immunofluorescence analysis. PC12 cells were washed in PBS and 
fixed in 4% paraformaldehyde for 30 minutes at room temperature. 
For quadriceps and soleus muscles, cryosections were prepared using 
a Cryocut 1800 cryostat (Leica) at 10 μm. Staining was performed 
using the indicated antibodies, mounted using Vectashield medium 
(Vector Laboratories), and sealed with nail polish. We scored AR 
translocation from cytoplasm to nucleus as described previously (59, 
60), using a value of 4 for nuclear fluorescence much greater than 
cytoplasmic fluorescence, 3 for nuclear fluorescence greater than 
cytoplasmic fluorescence, 2 for nuclear fluorescence equal to cyto-
plasmic fluorescence, 1 for nuclear fluorescence less than cytoplasmic 
fluorescence, and 0 for nuclear fluorescence much less than cytoplas-
mic fluorescence. The reported scores represent data from 50 cells per 
time point. To distinguish between type I and type II fibers, FITC-con-
jugated donkey anti-mouse IgM was used against A4.840 and Alexa 
Fluor 555 anti-mouse IgG was used against Ab-2. Fluorescence images 
were acquired using a Zeiss Axio Imager microscope. To calculate per-
centage of AR aggregation, AR-positive nuclear puncta were manually 
counted and divided by the total number of nuclei as quantified by 
ImageJ (NIH). To calculate fiber type size, the cross-sectional area of 
each fiber within a ×40 field was quantified in triplicate using ImageJ, 
and fiber type was discriminated by antibody stain.
CAG repeat tract-length was verified by sequencing. The modified 
targeting construct containing amino acids 31–484 of human AR exon 
1 and K385,518R mutations replaced mouse AR exon 1 by homolo-
gous recombination in JM8.F6 ES cells (57). Correct targeting of the 
AR113Q-KRKR allele was verified through Southern blot analysis 
using 5′ and 3′ probes falling outside of the targeted construct (Fig-
ure 2A). Three clones of correctly targeted ES cells were selected by 
neomycin resistance, karyotyped to verify euploidy, transiently trans-
fected with Cre recombinase to excise the floxed neomycin resistance 
cassette, and injected into C57BL/6J blastocysts obtained from mat-
ing C57BL/6-BrdCr-Hsd-Tyrc females with C57BL/6-BrdCrHsd-Tyrc 
males. These blastocysts were then implanted in pseudopregnant 
C57BL/6J females. All ES cell procedures were performed by the Uni-
versity of Michigan Transgenic Animal Model Core.
Mouse breeding and care. ES cell implantations yielded 8 chimeric 
males in total, which were then mated with albino C57BL/6J females 
(Jackson Laboratory) to sire AR113Q-KRKR F1 female mice hetero-
zygous for the targeted allele. Germline transmission of the targeted 
AR allele was indicated by black coat color and confirmed by PCR 
genotyping. These females were bred to C57BL/6J WT males to gen-
erate AR113Q-KRKR males for use in this study and AR113Q-KRKR 
heterozygous females to maintain the line. Mice were group housed 
in a specific pathogen–free (SPF) facility and provided with chow and 
water ad libitum. Genotypes were verified by PCR of DNA harvested 
from tail biopsies obtained shortly after weaning, using the forward 
primer 5′-CCAGAATCTGTTCCAGAGCGTG-3′ and the reverse prim-
ers 5′-TGTTCCCCTGGACTCAGATG-3′ and 5′-GCACTCCAGGGC-
CGACTGCG-3′ in a 2:2:1 ratio, respectively.
Mouse phenotyping and tissue collection. Every 2 weeks beginning 
at 8 weeks of age, male mice were weighed and forelimb strength was 
measured by grip strength meter (Columbus Instruments). Follow-
ing acclimation to the instrument, mice were allowed to grip the tri-
angular pull bar with forelimbs only and were then pulled backward 
horizontally; the average peak tension value from 5 consecutive grip 
trials was reported as the grip strength for each mouse. Disease onset 
was defined as the age at which grip strength was 10% less than the 
mean of age-matched controls. Skeletal muscles (quadriceps, gastroc-
nemius, soleus, TA, LABC), spinal cord, testis, and seminal vesicles 
were collected from adult males 13 to 15 weeks old and weighed or 
Table 1. Significantly enriched Gene Ontology categories related to 
mitochondria and energy metabolism
GO term Gene no. P value (Bonferroni)
Mitochondrion 49 3.43 × 10–8
Mitochondrial part 29 1.30 × 10–7
Mitochondrial envelope 22 2.07 × 10–5
Mitochondrial inner membrane 18 1.49 × 10–4
Mitochondrial membrane 20 1.61 × 10–4
Organelle inner membrane 18 3.08 × 10–4
Generation of precursor metabolites and energy 16 3.89 × 10–3
Electron transport chain 11 4.01 × 10–3
Oxidation reduction 26 6.30 × 10–3
Respiratory chain 8 6.49 × 10–3
GO, Gene Ontology.
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ductor implemented in the R statistical environment; P values were 
adjusted for multiple comparisons using FDR as described previously 
(61–64). Expression values were also inspected for quality control by 
principal components analysis. Genes were considered significantly 
responsive to androgen if they demonstrated a 1.5-fold or greater 
activation or repression in the R1881-treated samples compared with 
controls and an adjusted P value of 0.05 or less. Genes selected in this 
manner and relevant information (probe set ID, statistics, expression 
values, gene name, symbol, and links to online databases) were output 
into Excel for ranking by fold change values and determining the num-
bers used for Venn diagrams.
For RNA-Seq, the software package Tuxedo Suite was used for 
alignment, differential expression analysis, and postanalysis diag-
nostics (65–67). The reference transcriptome (UCSC mm10) (http://
genome.ucsc.edu/) was used for alignment. Expression quantitation 
and differential expression analysis were performed using CuffDiff 
(Cufflinks version 2.1.1). Genes and transcripts were identified as dif-
ferentially expressed based on 3 criteria: test status = OK, FDR <0.05, 
and fold change ≥ 1.5. Analysis of differentially expressed genes to 
identify significantly enriched functional categories was performed 
using DAVID. The heat map was plotted in R using the gplots and 
RColorBrewer packages.
Study approval. The University of Michigan Committee on Use 
and Care of Animals approved all procedures involving mice in com-
pliance with the Guide for the Care and Use of Laboratory Animals (8th 
ed. National Academies Press. Revised 2011).
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Orchiectomy. Adult male mice underwent orchiectomy following 
induction of anesthesia by 5% isoflurane and maintenance by 1.5% 
to 2% isoflurane. The abdomen was cleaned and shaved, and a 5-mm 
incision was made at the level of the hind legs. The vas deferens and 
spermatic cord were visualized, separated, and ligated with nonab-
sorbable silk sutures. The testes were removed, and the incision was 
closed with absorbable surgical suture. Carpofen was given daily at 
5 μg/g body weight by s.c. injection for 3 days after surgery. Three 
weeks after surgery, mice were treated with 200 μg testosterone pro-
pionate (Sigma-Aldrich) or sesame oil by i.p. injection. Tissue was har-
vested 16 hours after injection and stored in liquid nitrogen.
Gene-expression analysis. Total RNA was extracted from PC12 cells 
and from testes, prostate, quadriceps, and soleus muscles from mice 
with Trizol (Sigma-Aldrich). The RNA samples were then reverse tran-
scribed with High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) according to the manufacturer’s recommendations. qPCR 
was carried out using FastStart TaqMan Probe Master Mix (Roche) on 
software supplied with a 7500 Real-Time PCR SDS System (Applied 
Biosystems) and using gene-specific primers with FAM-labeled probes 
from Applied Biosystems (Mouse: Ar, Mm00442688_m1; Chrna1, 
Mm00431627_m1; Errfi1, Mm00505292_m1; Fkbp5, Mm00487401_
m1; Hsd3b1, Mm00476184_g1; Igf1r, Mm00802831_m1; Irs2, 
Mm03038438_m1; Myod1, Mm00499518_m1; Myog, Mm00446194_
m1; Nkx3-1, Mm00440479_m1; Pbsn, Mm00444381_m1; Spdef, 
Mm00600221_m1; Steap4, Mm00475405_m1; Wipi1, Mm00461219_
m1; Zbtb10, Mm01281740_m1. Rat: Baiap2, Rn00589411_m1; Chst1, 
Rn01484520_m1; Ppard, Rn00565707_m1). Relative expression lev-
els were calculated by normalizing to the expression of 18S rRNA. For 
GeneChip microarray analysis, cDNA samples from PC12 cells were 
applied to an Affymetrix Mouse Gene ST 2.1 Plate by the University 
of Michigan MicroArray Core. For RNA-Seq, cDNA was prepared into 
sequencer-ready fragment libraries using the Illumina TruSeq mRNA-
Seq Sample Prep Kit according to the manufacturer’s recommended 
protocols and sequenced on the Illumina HiSeq 2000 using the manu-
facturer’s recommended protocols for paired-end, 100 nt sequencing. 
Samples were multiplexed into pools of 6 samples each, and each pool 
was sequenced on 1 lane of the sequencer. All original microarray and 
RNA-Seq data were deposited in the NCBI’s Gene Expression Omni-
bus (microarray data, GEO GSE50383; RNA-Seq data, GSE60691).
Statistics. To determine statistical significance, data sets were 
analyzed using unpaired 2-tailed Student’s t test, ANOVA with New-
man-Keuls multiple comparison test, or Mantel-Cox log-rank test in 
Prism 6 (GraphPad). Differences between means were defined as sig-
nificant at P < 0.05.
For GeneChip analysis, probe data were inspected for quality 
control by signal density distribution and normalized unscaled SEM 
estimates. Relative expression values were calculated using a robust 
multiarray average (RMA), with oligo and limma packages of biocon-
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